MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Pfizer
M.D. Anderson Cancer Center
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
M.D. Anderson Cancer Center
University of Oklahoma
University of Miami
K36 Therapeutics, Inc.
University of Utah
M.D. Anderson Cancer Center
AHS Cancer Control Alberta
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
University of Maryland, Baltimore
Monash University
Monash University
Monash University
Monash University
Dana-Farber Cancer Institute
Washington University School of Medicine
Institute of Hematology & Blood Diseases Hospital, China
Memorial Sloan Kettering Cancer Center
Barbara Ann Karmanos Cancer Institute
Essen Biotech
University of Arkansas
Second Affiliated Hospital, School of Medicine, Zhejiang University
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech Co., Ltd
University of Rochester
Shenzhen University General Hospital
OriCell Therapeutics Co., Ltd.
Heidelberg Pharma AG
Insel Gruppe AG, University Hospital Bern
Nantes University Hospital
Peking Union Medical College Hospital
Monash University
Xuzhou Medical University
Hellenic Society of Hematology
University Hospital, Clermont-Ferrand
The Affiliated People's Hospital of Ningbo University